Key result
Ticagrelor yields ~16-point lower post-maintenance platelet reactivity vs. clopidogrel in ACS.
Why the study?
The PLATO trial demonstrated the superiority of ticagrelor over clopidogrel for preventing ischemic events in patients with acute coronary syndromes, motivating a direct comparison of their antiplatelet effects in this population.
Does ticagrelor achieve greater inhibition of platelet function compared with clopidogrel in patients with acute coronary syndromes?
RCT (n=69)
Randomized
Does ticagrelor achieve greater inhibition of platelet function compared with clopidogrel in patients with acute coronary syndromes?
Ticagrelor provides more potent and consistent platelet inhibition than clopidogrel during both initial loading and maintenance therapy in patients with acute coronary syndromes, and its antiplatelet effect is not attenuated by proton pump inhibitor use.
Answers are grounded in this paper and cite their sources.
Ticagrelor maintenance yields greater platelet inhibition than clopidogrel; extends PLATO findings to this cohort but leaves clinical translation open.
Objectives The PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy aimed to compare the antiplatelet effects of clopidogrel and ticagrelor in patients with acute coronary syndromes. Background The PLATO study demonstrated superiority of ticagrelor over clopidogrel in the prevention of ischemic events in patients with acute coronary syndromes. Methods Patients were randomized to receive either clopidogrel (300- to 600-mg loading dose [LD], 75 mg/day) or ticagrelor (180-mg LD, 90 mg twice daily). The effects of maintenance therapy were studied in 69 patients pre- and 2 to 4 h post-dose after at least 28 days. The LD effect was studied in 24 clopidogrel-naive patients. Light transmittance aggregometry (adenosine diphosphate 5 to 20 μM), VerifyNow P2Y12, and VASP phosphorylation assays were performed. Results During maintenance therapy, ticagrelor achieved greater suppression of platelet reactivity compared with clopidogrel. The mean maximum light transmittance aggregometry responses (adenosine diphosphate 20 μM) post-maintenance dose were 44±15% for clopidogrel and 28±10% for ticagrelor (p<0.001). High platelet reactivity was seen more frequently in the clopidogrel group. Proton pump inhibitor use was associated with higher platelet reactivity with clopidogrel but not ticagrelor. The ticagrelor LD also achieved greater inhibition of platelet aggregation compared with the clopidogrel LD. Conclusions Ticagrelor achieves greater antiplatelet effect than clopidogrel in patients with acute coronary syndromes, both in the first hours of treatment and during maintenance therapy.
No takes yet. Share an insight, caveat, or question.
Storey et al. (2010) conducted an RCT in Acute coronary syndromes (n=69). Ticagrelor vs. Clopidogrel (300- to 600-mg loading dose, 75 mg/day) was evaluated on Mean maximum light transmittance aggregometry response (adenosine diphosphate 20 μM) post-maintenance dose (p=<0.001). Ticagrelor achieved greater platelet reactivity suppression than clopidogrel in ACS patients, with post-maintenance LTA responses of 28±±15%.
Synapse has enriched 10 related papers. Consider them for comparative context: